A Phase 3 interventional study of GP681 40mg and GP681 Simulant in Influenza, sponsored by Jiangxi Qingfeng Pharmaceutical Co. Ltd.. Recruiting at 1 site in China. Open to participants aged 12 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-05.
Sponsored by Jiangxi Qingfeng Pharmaceutical Co. Ltd. (part of Qingfeng Pharmaceutical Group Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 173 studies in Influenza, Human with a site in China — 30 open to participants now, 37 under way, 10 of them phase 3. Influenza, Human · China.
Among the 173 studies in Influenza, Human with a site in China, this one is the 53rd largest by planned enrollment of the 157 interventional ones that give a count, is one of 17 that started in 2024, is one of 46 in phase 3, reaches primary completion later than 30 of the 36 other live ones, and was the 132nd registered.
2,361 studies on the registry are indexed under Influenza, Human; 186 are open to participants now.
Browse Influenza, Human studies →30 of the 173 studies in Influenza, Human with a site in China are open now. Recruiting first, the newest first:
Sinovac Biotech Co., Ltd · Sites in China
Ages 18–45 · Women only · Healthy volunteers
Hoffmann-La Roche · Sites in China
Ages 5+ · Healthy volunteers
Ab&B Bio-tech Co., Ltd.JS · Sites in China
Ages 6 mo+ · Healthy volunteers
Shanghai Institute Of Biological Products · Sites in China
Ages 60+ · Healthy volunteers
Capital Medical University · Sites in China
Ages 12+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 124 Influenza, Human studies recruiting now, 67 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 69 take healthy volunteers.
This study: 12 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
173 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 28 · Phase 2 22 · Phase 3 49 · Phase 4 43
First in 2004; this study’s year is marked. 17 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 748 is above the median of 228 across 1,959 interventional studies indexed under Influenza, Human.
Median enrollment 360 across the 157 interventional studies, 230 across the 14 observational. Of the 115 that completed or were terminated, 9 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
97 of 173 have an industry lead sponsor. The 10 most frequent:
This study is registered under Jiangxi Qingfeng Pharmaceutical Co. Ltd., one of the names counted as Qingfeng Pharmaceutical Group Co., Ltd.. Under that name alone:
Jiangxi Qingfeng Pharmaceutical Co. Ltd. is the lead sponsor of 32 studies on the registry; 3 are open to participants now.
Qingfeng Pharmaceutical Group Co., Ltd. has 8 studies filed under Influenza, Human — fewer than ten, so there is no comparison to draw.
14 of the studies in Influenza, Human with a site in China that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07229547Phase 3Ruijin HospitalA Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Safety and Efficacy of Onradivir Tablets in Participants Aged 12 to 17 Years With Uncomplicated Influenza A. | 2026-12-01 |
| NCT07236814Phase 3Capital Medical UniversitySuraxavir Marboxil And Oseltamivir for Influenza Prophylaxis Under a Hospital-based Setting | 2027-03-01 |
| NCT07893847Phase 3Capital Medical UniversityEvaluation of the Efficacy and Safety of 102D-6 in the Treatment of Acute Uncomplicated Influenza | 2027-03-30 |
| NCT07827599Phase 3Hoffmann-La RocheA Study to Confirm Efficacy of a Single Dose of Baloxavir Marboxil in the Post-exposure Prophylaxis (PEP) of Influenza Virus Infection in Chinese Participants | 2027-04-30 |
| NCT06574503Phase 3Jiangxi Qingfeng Pharmaceutical Co. Ltd.Study to Assess the Efficacy and Safety of GP681 Versus Placebo for Postexposure Prophylaxis Against Influenza | 2027-07-30 |
Add all 14 to your calendar (.ics) → With an account.
Among the 173 studies in Influenza, Human with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Index patients who are infected with influenza virus (Q-PCR positive) can be treated with anti-influenza drugs if their influenza symptoms onset was within 48 hours of screening. Their eligible households will be randomized to either GP681 tablets or placebo if at least 1 household contacts have not received influenza vaccine with 6 months of screening and if all household contacts screen negative for influenza infection. The main endpoints are assessed based on multiple respiratory swabs, obtained from household contacts up to Day 10, and through the assessment of symptoms.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Index patients(IPs)
Household contacts of index patients:
Exclusion Criteria:
Household contacts of index patients:
Women who are pregnant, breastfeeding, or have a positive pregnancy test at the predose examinations. The following female patients who have documentation of either a or below do not need to undergo a pregnancy test at the predose examinations:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
atients in the GP681 tablet 40mg group will receive a single oral dose of GP681 tablet 40mg with water.
Drug: GP681 40mg
Patients in the Placebo group will receive a single oral dose of GP681 Simulant 40mg with water.
Drug: GP681 Simulant
2X20mg tablets taken orally
Placebo tablets matching GP681 40mg
Proportion of household members who are infected with influenza virus (Q-PCR positive), and present with fever and at least one influenza symptom with severity of moderate or severe in the period from Day 1 to Day 10.
Defined as the proportion of household members having body temperature (axillary)≥37.3°C, having symptom of influenza (respiratory symptoms or systemic symptoms) with a severity of "2, Moderate" or "3, Severe" assessed in the subject diary, and influenza virus positive assessed by Q-PCR.
Time frame: up to Day 10
Proportion of household members who are infected with influenza virus (Q-PCR positive), and present with fever or at least one influenza symptom with severity of moderate or severe in the period from Day 1 to Day 10.
Defined as the proportion of household members having body temperature (axillary)≥37.3°C, or having symptom of influenza (respiratory symptoms or systemic symptoms) with a severity of "2, Moderate" or "3, Severe" assessed in the subject diary, and influenza virus positive assessed by Q-PCR.
Time frame: up to Day10
Proportion of household members with influenza virus infection in the period from Day 1 to Day 10
Defined as the proportion of subjects having influenza virus positive assessed by RT-PCR regardless of body temperature or influenza symptoms.
Time frame: up to Day10
Time from study treatment to the time when fever, at least one influenza symptom with severity of moderate or severe, and influenza virus infection were observed.
Defined as the later timepoint of the following (1) and (2): 1. Timepoint when body temperature (axillary) rises first to " 37.3°C 2. Timepoint when an influenza symptom was first assessed as"2, Moderate" or "3, Severe" in the subject diary. If a household member does not have a body temperature (axillary) of "37.3°C or influenza symptom was not assessed as"2, Moderate" or "3, Severe" in the period from Day 1 to Day 10, the subject will be handled as a censored case.
Time frame: up to Day10
Time from study treatment to the time when fever or at least one influenza symptom (respiratory symptom or systemic symptom), and influenza virus infection are observed.
Defined as the timepoint of the following (1) and (2), whichever is earlier: 1. Timepoint when body temperature (axillary) rises first to " 37.3°C 2. Timepoint when an influenza symptom was first assessed as"2, Moderate" or "3, Severe" in the subject diary. If a subject does not have a body temperature (axillary) of "37.5°C and influenza symptoms (respiratory symptoms and systemic symptoms) were not assessed as 2, Moderate or 3, Severe in the period from Day 1 to Day 10, the subject will be handled as a censored case.
Time frame: up to Day10
Proportion of asymptomatic influenza-infected (Q-PCR positive) household members in the period from Day 1 to Day 10
Defined as the proportion of household members having body temperature (axillary) \< 37.5°C, influenza symptoms all assessed as 0, Absent or 1, Mild , and influenza virus positive assessed by Q-PCR.
Time frame: Up to Day 10
Proportion of household members who are not infected with influenza virus (Q-PCR negative) and present with fever and at least one influenza symptom with severity of moderate or severe in the period from Day 1 to Day 10
Defined as the proportion of household members having body temperature (axillary) "37.3°C, having symptom of influenza (respiratory symptoms or systemic symptoms) with a severity of "2, Moderate" or "3, Severe" assessed in the subject diary, and influenza virus negative at all time points assessed by Q-PCR.
Time frame: Up to Day 10
Proportion of household members who are infected with influenza virus (Q-PCR positive) in the period from Day 1 to Day 10, with virus subtype consistent with index patient
Defined as the proportion of household members who are infected with influenza virus (Q-PCR positive) in the period from Day 1 to Day 10,and the virus subtype of household members are consistent with index patient
Time frame: Up to Day 10
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2024 (actual). Primary completion is estimated for Jul 2027, 31 months after the start.
Of 119 industry-sponsored phase 3 interventional studies under Influenza, Human, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 14. This study's planned 31 months is above that.
Counting every sponsor, half of 154 studies reached it within 8 months; a quarter within 4 and three quarters within 15.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: GP681
Jiangxi Qingfeng Pharmaceutical Co. Ltd. →